Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.

Cancer research - 1 Apr 2017

Lu Yanxin, Kwintkiewicz Jakub, Liu Yang, Tech Katherine, Frady Lauren N, Su Yu-Ting, Bautista Wendy, Moon Seog In, MacDonald Jeffrey, Ewend Matthew G, Gilbert Mark R, Yang Chunzhang, Wu Jing

Abstract excerpt

Mutations in isocitrate dehydrogenase (IDH) are the most prevalent genetic abnormalities in lower grade gliomas. The presence of these mutations in glioma is prognostic for better clinical outcomes with longer patient survival. In the present study, we found that defects in oxidative metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In addition, temozolomide (TMZ) treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Phthalazines

Share to Piperazines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 28202508
DOI: 10.1158/0008-5472.CAN-16-2773
PMCID: PMC5380481

Genes

IDH1
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.PMID 28202508Read ↗

DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.Semantic proximity Read ↗

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Semantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.Semantic proximity Read ↗

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics DevelopmentSemantic proximity Read ↗

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivitySemantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.